Direkt zum Inhalt
Merck
Alle Fotos(1)

Key Documents

View All Documentation

SML0150

Sigma-Aldrich

Tolcapon

≥98% (HPLC)

Synonym(e):

3,4-Dihydroxy-4′-methyl-5-nitrobenzophenon, Ro 40-7592

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C14H11NO5
CAS-Nummer:
134308-13-7
Molekulargewicht:
273.24
MDL-Nummer:
MFCD00866569
UNSPSC-Code:
12352200
PubChem Substanz-ID:
329825198
NACRES:
NA.77

Assay

≥98% (HPLC)

Form

powder

Lagerbedingungen

desiccated

Farbe

yellow

Löslichkeit

DMSO: ≥15 mg/mL

Ersteller

Roche

Lagertemp.

2-8°C

SMILES String

Cc1ccc(cc1)C(=O)c2cc(O)c(O)c(c2)[N+]([O-])=O

InChI

1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3

InChIKey

MIQPIUSUKVNLNT-UHFFFAOYSA-N

Angaben zum Gen

human ... COMT(1312)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Anwendung

Tolcapone may be used in COMT-mediated cell signaling studies.
Tolcapone has been used in methyltransferase assay in human embryonic kidney 293 cells.

Biochem./physiol. Wirkung

Inhibition of catechol-O-methyltransferase by tolcapone increases the half-life and bioavailabilty of levodopa. It therefore is an effective adjunctive therapy in patients with Parkinson′s disease with motor response fluctuations.
Tolcapone is an orally active catechol-O-methyltransferase (COMT) inhibitor. It inhibits both central and peripheral COMT. Tolcapone crosses the blood-brain barrier, and has been used for L-DOPA adjunct therapy in the treatment of Parkinson′s Disease.

Leistungsmerkmale und Vorteile

This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Piktogramme

Environment
GHS09

Signalwort

Warning

H-Sätze

H400

Gefahreneinstufungen

Aquatic Acute 1

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Sandro Zambito Marsala et al.
Clinical neuropharmacology, 35(4), 185-190 (2012-07-19)
Catechol-O-methyltransferase (COMT) inhibitors are drugs commonly used in the management of patients with Parkinson disease complicated by motor fluctuations. Among them, entacapone is the most commonly used. Tolcapone has been reintroduced in patients where entacapone has proved to be ineffective
Andrew J Lees
CNS neuroscience & therapeutics, 14(1), 83-93 (2008-05-17)
The relative efficacy has not been adequately established for the two catechol-O-methyltransferase (COMT) inhibitors that are currently available for adjunctive therapy in Parkinson's disease; tolcapone and entacapone. A recent Cochrane meta-analysis of 14 studies in 2566 patients, conducted to assess
H Baas et al.
Journal of neurology, neurosurgery, and psychiatry, 63(4), 421-428 (1997-10-29)
More than 50% of patients with Parkinson's disease develop motor response fluctuations (the "wearing off" phenomenon) after more than five years of levodopa therapy. Inhibition of catechol-O-methyltransferase by tolcapone has been shown to increase levodopa bioavailability and plasma elimination half
Gillian M Keating et al.
CNS drugs, 19(2), 165-184 (2005-02-09)
Tolcapone (Tasmar) is a selective, reversible inhibitor of peripheral and central catechol-O-methyltransferase (COMT). Results of well designed studies indicate that oral tolcapone is an effective adjunct to levodopa plus a peripheral dopa-decarboxylase inhibitor (DDCI) in patients with fluctuating Parkinson's disease.
Jenny J Fischer et al.
Toxicological sciences : an official journal of the Society of Toxicology, 113(1), 243-253 (2009-09-29)
Capture compound mass spectrometry (CCMS) is a novel technology that helps understand the molecular mechanism of the mode of action of small molecules. The Capture Compounds are trifunctional probes: A selectivity function (the drug) interacts with the proteins in a
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.